Type stringclasses 2
values | Section_id stringclasses 4
values | Primary_id stringlengths 11 11 | Secondary_id stringlengths 0 11 | Statement stringlengths 34 385 | Label stringclasses 2
values | Primary_evidence_index listlengths 1 65 | Secondary_evidence_index listlengths 0 73 | Primary_ct stringlengths 1.11k 16.3k | Secondary_ct stringlengths 101 16.3k | __index_level_0__ stringlengths 36 36 |
|---|---|---|---|---|---|---|---|---|---|---|
Single | Results | NCT01091168 | Patients in the control group of the primary trial had a median Overall Survival of less than a year. | Entailment | [
0,
1,
2,
3,
11,
12,
13,
14,
15,
9,
17
] | [] | {'Clinical Trial ID': 'NCT01091168', 'Intervention': ['INTERVENTION 1: ', ' Vinflunine', ' Patients randomised in the test arm (arm A) received VFL at the dose of 280 mg/m² on day 1 of each cycle every 3 weeks, over a 20-minute intravenous (IV) infusion. Cycles were repeated every 3 weeks.', ' vinflunine: 280 mg/m2 ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5bc0d21d-a040-4d30-b0c7-8793cba6aba8 | |
Comparison | Intervention | NCT00952731 | NCT00956813 | Cohort 2 in the primary trial and the secondary trial but receive daily placebo doses. | Entailment | [
5,
6,
7,
8,
9
] | [
3,
4,
5
] | {'Clinical Trial ID': 'NCT00952731', 'Intervention': ['INTERVENTION 1: ', ' Treatment Gel + Oral Placebo', ' 4-hydroxytamoxifen gel 2mg/breast applied daily. Oral placebo taken daily.', ' oral placebo: Oral placebo taken daily for 4-10 weeks.', ' afimoxifene: 2mg/breast applied daily in the form of a gel for 4-10 w... | {'Clinical Trial ID': 'NCT00956813', 'Intervention': ['INTERVENTION 1: ', ' Flaxseed', ' Patients receive 1 Nutrigrad™ flaxseed bar containing 7.5 grams flaxseed, 410 mg lignans,once daily.', 'INTERVENTION 2: ', ' Placebo', ' Patients Identical looking bar with same calorie and total fat content but without flaxsee... | 9bcbadcc-ae56-4254-ac8b-ab5d35e80eba |
Single | Adverse Events | NCT00091442 | There were more cases of Febrile neutropenia than leukopenia observed in the primary trial, but less cases of neutropenia than leukopenia. | Contradiction | [
0,
2,
3,
4
] | [] | {'Clinical Trial ID': 'NCT00091442', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel', ' Docetaxel monotherapy: Docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.', 'INTERVENTION 2: ', ' DOXIL+Docetaxel', ' DOXIL and docetaxel combination: DOXIL 30 mg/m2 so... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5a1358af-f51b-49f8-b1c0-99a0b108b0a2 | |
Single | Eligibility | NCT02635737 | Patients with implantable cardioverter defibrillators are excluded from the primary trial. | Entailment | [
6,
7
] | [] | {'Clinical Trial ID': 'NCT02635737', 'Intervention': ['INTERVENTION 1: ', ' Sentimark Device Placement', ' Sentimark device placed in women having mastectomy surgery', ' Sentimark: Placement of a metallic clip with paramagnetic properties for tumour localisation'], 'Eligibility': ['Inclusion Criteria:', ' Participa... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ed0e1b04-aea7-4da0-922f-2be69c768c09 | |
Single | Results | NCT01439711 | One patient in the primary trial had a 0.98 cm3 increase in Total MRI Functional Tumor Volume (FTV) over 3 months, almost 1cm3 less than average. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01439711', 'Intervention': ['INTERVENTION 1: ', ' Letrozole + MRI', ' Protocol Therapy will consist of 6 months of letrozole, administered orally at a dose of 2.5 mg/day. Patients will have a bilateral MRI for disease evaluation at months 3 and 6.'], 'Eligibility': ['Eligibility Criteria:', ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 73d323e7-1a38-49d4-97f4-a15f1664fb3e | |
Single | Eligibility | NCT02010021 | A patient has recently had an oophorectomy,they are excluded from the primary trial. | Contradiction | [
10,
11
] | [] | {'Clinical Trial ID': 'NCT02010021', 'Intervention': ['INTERVENTION 1: ', ' No Drug Treatment', ' Post-menopausal women with stage I-III breast cancer with surgical resection of tumor and tumor tissue will be used to study cell growth signaling pathways ex-vivo.', 'INTERVENTION 2: ', ' Letrozole-presurgical', ' Pat... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 02dea6a3-d94f-4650-bf4f-be8fdb0a382f | |
Single | Results | NCT00943670 | The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle, before T-DM1 intravenous (IV) infusion. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [] | {'Clinical Trial ID': 'NCT00943670', 'Intervention': ['INTERVENTION 1: ', ' T-DM1', ' Trastuzumab emtansine (T-DM1) was administered to participants by intravenous (IV) infusion on Day 1 of every 3 week cycle at a dose of 3.6 mg/kg.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically documented, locally advan... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4c8a124b-f015-42e2-8ad3-6168f21fe705 | |
Single | Adverse Events | NCT00130533 | Nobody in cohort 1 of the primary trial suffered from Hyperbilirrubinemia. | Contradiction | [
0,
3
] | [] | {'Clinical Trial ID': 'NCT00130533', 'Intervention': ['INTERVENTION 1: ', ' Xeloda (Capecitabine)', ' 1000 mgrs/m2 twice a day, tablets, 8 cycles', 'Capecitabine', 'INTERVENTION 2: ', ' Observation', ' Observation. No intervention.'], 'Eligibility': ['Inclusion Criteria:', ' Written informed consent.', ' Histolog... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | fb43432d-6c1b-4ff7-aea8-72bc2519a12d | |
Single | Eligibility | NCT00005879 | There are criteria for PRIOR CONCURRENT THERAPY, PATIENT CHARACTERISTICS and DISEASE CHARACTERISTICS for entry to the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38,
39,
40,
41,
42,
43,
44,
45,
46,
47,
48,
49,
50,
51,
52,
53,
54... | [] | {'Clinical Trial ID': 'NCT00005879', 'Intervention': ['INTERVENTION 1: ', ' Placebo', ' Placebo', ' Placebo: matched tablet dialy', 'INTERVENTION 2: ', ' Arzoxifene', ' LY353381, 20 mg daily', ' arzoxifene: one tablet daily'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Current random fine needle breast aspira... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d6df95f5-472f-4b14-9cd4-5d5ef238175a | |
Single | Eligibility | NCT00553410 | A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial due to her age. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33
] | [] | {'Clinical Trial ID': 'NCT00553410', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Continuous Letrozole', ' Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)', ' Letrozole: Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously', 'INTERVENTION 2: ', ' Arm B: Intermittent Let... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | bd8c39c6-96a3-40f8-80e6-6cbb6bdaecb5 | |
Single | Eligibility | NCT00982319 | Only Post menopausal women can enter the primary trial, as long as they do not have prior hormone replacement therapy. | Contradiction | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT00982319', 'Intervention': ['INTERVENTION 1: ', ' Broccoli Sprout Extract and Mango Juice', ' Patients will be randomized to 14 day intervention of broccoli sprout extract consisting of a consistent dose of sulforaphane dissolved in mango juice. All women will be on a cruciferous free diet f... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 52ae415a-d8ab-48f5-abcb-9e8c5bb4fc83 | |
Comparison | Intervention | NCT01425268 | NCT01373671 | CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and saline is used in both of the study groups in the secondary trial. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01425268', 'Intervention': ['INTERVENTION 1: ', ' AeroForm Tissue Expansion', ' AeroForm Tissue Expansion inflation with carbon dioxide by remote control', ' AeroForm Tissue Expansion: The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy... | {'Clinical Trial ID': 'NCT01373671', 'Intervention': ['INTERVENTION 1: ', ' FFDM and DBT', ' FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration', 'INTERVENTION 2: ', ' FFDM Only', 'FFDM exam only'], 'Eligibility': ['Inclusion Criteria:', ' All subjects enrolled into the collection study must:', ' Provide signe... | 3bb3f3d5-e2e8-4cde-9d4f-dfc4b25c0b70 |
Comparison | Intervention | NCT01289353 | NCT00429182 | the primary trial and the secondary trial share at least one drug in their chemotherapy regiment. | Entailment | [
0,
3
] | [
0,
2,
3
] | {'Clinical Trial ID': 'NCT01289353', 'Intervention': ['INTERVENTION 1: ', ' ChemoRT', ' Concurrent Carboplatin and Radiotherapy', ' Carboplatin: IV, weekly for 6 weeks, AUC of 2.0', ' 3D-RT or IMRT: From week 2 to week 4 in the 6-week Carboplatin treatment: Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 tim... | {'Clinical Trial ID': 'NCT00429182', 'Intervention': ['INTERVENTION 1: ', ' High-dose Chemotherapy', ' Carboplatin + Cyclophosphamide + Thiotepa', ' Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.', ' Thiotepa : 120 mg/m^2 by vein days -6... | f820384b-0bf5-4f2e-96fd-2c8b13a4646c |
Single | Adverse Events | NCT00448591 | Only two types of adverse events occurred in more than 1% of patient in cohort 1 of the primary trial. | Entailment | [
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT00448591', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab', ' Participants received bevacizumab 15 mg/kg iv on Day 1 of each 3 week cycle, or 10 mg/kg iv on Day 1 of each 2 week cycle (weekly equivalent dose of 5 mg/kg/week) along with Taxane-based chemotherapy as prescribed'], 'Eligibil... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f7410166-82a7-4d15-8a04-47287ef6884c | |
Single | Eligibility | NCT00121836 | Patients that are not willing to sign and give written informed consent for participation of the primary trial will still be included. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT00121836', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev', ' First Study Treatment Phase:', ' Capecitabine 1000 mg/m² oral (PO) twice-daily, Days 1-15 of each 3-week cycle (28 doses per cycle); bevacizumab 15 mg/kg intravenous (IV) inf... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 80726ab0-e8e4-4c42-860b-fdedad407517 | |
Comparison | Intervention | NCT02725801 | NCT04030104 | Neither the primary trial or the secondary trial have placebo groups. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT02725801', 'Intervention': ['INTERVENTION 1: ', ' One-port', ' intervention is placement of one-port tissue expander at time of reconstruction', ' Allergen one-port tissue expander placement: patients will be randomized to receive a one port or two port tissue expander for breast reconstruc... | {'Clinical Trial ID': 'NCT04030104', 'Intervention': ['INTERVENTION 1: ', ' IUS Alone', 'IUS alone imaging', 'INTERVENTION 2: ', ' Imagio (IUS+OA)', 'IUS+OA imaging'], 'Eligibility': ['Inclusion Criteria:', ' One analyzable mass per patient: BI-RADS 3 and 4a, 4b, 4c and 5 masses as declared by clinical site investig... | f2e1c4f6-2f62-4a5e-b033-d798ba781d1d |
Single | Results | NCT00036270 | In total Less than 10% of patients in the primary trial either had a disease relapse or died. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00036270', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' Exemestane (Aromasin®) 25 mg QD for 5 years.', 'INTERVENTION 2: ', ' Tamoxifen Followed by Exemestane', ' Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 2... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d42054cd-deb6-4436-941c-9e3a06c713cc | |
Comparison | Results | NCT02041429 | NCT00068588 | the primary trial and the secondary trial use Maximum Tolerated Dose Determined by Dose-limiting Toxicities as their outcome measurements. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02041429', 'Intervention': ['INTERVENTION 1: ', ' All Phase I Participants', ' Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib orally twice daily according to the established dose escalation schedule for 4 cycles', ' 1 cycle = 21 days Participants with stable disease or better will have the opp... | {'Clinical Trial ID': 'NCT00068588', 'Intervention': ['INTERVENTION 1: ', ' Arm 1', ' Capecitabine 800 mg/m2 BID for 14 days on days 2-15 of each 21 day cycle +GTI-2040 civ infusion 185 mg/m2/day on days 1-15 of cycle 1 and days 1-14 of each subsequent cycle,', 'INTERVENTION 2: ', ' Arm 2', ' Capecitabine 1000 mg/m... | 0507fbf8-3557-4ace-b015-5e106b96f6a9 |
Single | Eligibility | NCT00825734 | Patients with any of the following conditions will be excluded from the primary trial; grade 1 infection, unstable angina or a grade 4 hemorrhage within the last month. | Contradiction | [
87,
94,
95,
108,
117,
118,
119,
120
] | [] | {'Clinical Trial ID': 'NCT00825734', 'Intervention': ['INTERVENTION 1: ', ' Sorafenib and Ixabepilone', ' Oral targeted therapy and Systemic Chemotherapy'], 'Eligibility': ['Inclusion Criteria:', ' Age 18 years.', ' Histologically or cytologically confirmed breast cancer diagnosis', ' with metastatic disease. Pat... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 49ecc5a6-89be-48b6-85c5-c809c83f5baf | |
Comparison | Intervention | NCT00343382 | NCT00798135 | Cohort 2 of the primary trial recieves a lower dose of Pilocarpine than cohort 2 of the secondary trial recieves of oral itraconazole. | Entailment | [
3,
4,
5
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00343382', 'Intervention': ['INTERVENTION 1: ', ' Collective Placebo', ' Patients receive 1 capsule of placebo 2 times per day for 6 weeks and; patients receive 1 capsule of placebo 4 times per day for 6 weeks.', 'INTERVENTION 2: ', ' Pilocarpine 2 Times Per Day', ' Patients receive 5mg of... | {'Clinical Trial ID': 'NCT00798135', 'Intervention': ['INTERVENTION 1: ', ' Itraconazole', ' oral itraconazole 200mg a day until disease progression or unacceptable toxicities.'], 'Eligibility': ['Inclusion Criteria:', ' - Patients must have a pathologically confirmed diagnosis of invasive carcinoma of the breast. -... | 68792f63-d7b5-4570-bf8e-95e4cb8094e9 |
Comparison | Adverse Events | NCT00483223 | NCT00811135 | There are more cases of Intestinal perforation, Chest pain, death, Erysipelas and Pneumonia in the secondary trial than in the primary trial | Entailment | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT00483223', 'Intervention': ['INTERVENTION 1: ', ' Cisplatin or Carboplatin', ' Cisplatin or carboplatin (1 arm, 2 cohorts)', ' Cisplatin: Given intravenously on the first day of each 3-week treatment cycle at 75mg/m2. Participants may continue to receive study treatment as long as their dis... | {'Clinical Trial ID': 'NCT00811135', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + Bevacizumab + Capecitabine', ' Participants received IV trastuzumab (8 mg/kg) for first cycle and then 6 mg/kg for subsequent cycles followed by bevacizumab (15 mg/kg) on Day 1 of each treatment cycles along with capecitabine ad... | 2ddd64c7-98ef-4b06-9f01-e59d3731e8ca |
Comparison | Intervention | NCT01852032 | NCT01118624 | We cannot compare the doses and frequencies provided in the intervention sections of the secondary trial and the primary trial. | Entailment | [
0,
1,
2
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01852032', 'Intervention': ['INTERVENTION 1: ', ' Breast Cancer Patients', ' Tomosynthesis Breast Scanning is done and breast CT Scanning is done.'], 'Eligibility': ['Inclusion Criteria:', ' 35 years of age or older', ' While male patients will not be explicitly excluded, it is expected th... | {'Clinical Trial ID': 'NCT01118624', 'Intervention': ['INTERVENTION 1: ', ' Pralatrexate', ' Study drug 190 mg/m^2 for 2 to 4 weeks.'], 'Eligibility': ['Inclusion Criteria:', ' HER-2 negative advanced or metastatic breast cancer', ' Disease has become worse after at least 1 prior chemotherapy regimen for advanced o... | a1a5767f-07e7-4a33-a26f-586cf71a208d |
Single | Eligibility | NCT01326481 | Patients with Myocardial Infarction or Deep vein thrombosis within the last 3 months are excluded from the primary trial. | Entailment | [
10,
18
] | [] | {'Clinical Trial ID': 'NCT01326481', 'Intervention': ['INTERVENTION 1: ', ' Carotuximab (TRC105) Plus Capecitabine', ' All patients received TRC105 + capecitabine TRC105: IV (7.5 or 10 mg/kg weekly) Capecitabine: oral (1,000 mg/m2 BID)'], 'Eligibility': ['Inclusion Criteria:', ' Histologically proven advanced solid ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9c80fb61-66dc-4b3d-82b9-4fb62db89422 | |
Single | Intervention | NCT00181363 | The only difference between the interventions used in the primary trial is the patients location. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00181363', 'Intervention': ['INTERVENTION 1: ', ' Prone', 'Prone position', 'INTERVENTION 2: ', ' Supine', 'Supine position'], 'Eligibility': ['Inclusion Criteria:', ' Patients should have had breast-conserving surgery for breast cancer or DCIS (Ductal Carcinoma in Situ)', ' No indication ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6755a378-08bf-4e9b-a6de-166733d0307b | |
Comparison | Intervention | NCT00262834 | NCT01106898 | In the secondary trial and the primary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy compared to other patients. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3,
4
] | {'Clinical Trial ID': 'NCT00262834', 'Intervention': ['INTERVENTION 1: ', ' Vorinostat', ' Women in the vorinostat group were scheduled to receive 6 doses of oral vorinostat at 300 mg twice daily (bid), with the last dose administered by study personnel approximately 2 hours before the scheduled breast surgery (or bi... | {'Clinical Trial ID': 'NCT01106898', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Chemotherapy With or Without Maintenance Therapy)', ' SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of ... | b7f3e657-638b-4463-9639-4fb0da2be042 |
Comparison | Adverse Events | NCT00546156 | NCT00398567 | There are no cases of Vertigo, Abdominal distension or Neutropenia in the primary trial or the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | {'Clinical Trial ID': 'NCT00546156', 'Intervention': ['INTERVENTION 1: ', ' HR+, HER2-', ' Patients with Hormone Receptor Positive, HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4... | {'Clinical Trial ID': 'NCT00398567', 'Intervention': ['INTERVENTION 1: ', ' Part 2 - Expanded MTD Cohort', ' All subjects receiving HKI-272 (neratinib) in combination with trastuzumab (Herceptin) HKI-272: neratinib 240 mg daily by mouth Herceptin: Herceptin 4 mg/kg IV as a loading dose followed by Herceptin 2 mg/kg w... | 5498a85b-a086-4d5d-b677-9ae44646a382 |
Single | Eligibility | NCT00418457 | antibiotics within 10 days prior to beginning is acceptable for patients entering the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [] | {'Clinical Trial ID': 'NCT00418457', 'Intervention': ['INTERVENTION 1: ', ' General Anesthesia and Opioid', ' General anesthesia followed by opioid administration', ' General anesthesia and opioids: General anesthesia, usually with sevoflurane, and opioid analgesia', 'INTERVENTION 2: ', ' Regional Analgesia and Pro... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f3d2337e-6cd9-4e8c-b327-cbc48557b8dd | |
Single | Results | NCT00068588 | between the two Arms of the primary trial, cohort 1 vastly outperformed cohort 2 in terms of the number of patients with complete tumor response. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00068588', 'Intervention': ['INTERVENTION 1: ', ' Arm 1', ' Capecitabine 800 mg/m2 BID for 14 days on days 2-15 of each 21 day cycle +GTI-2040 civ infusion 185 mg/m2/day on days 1-15 of cycle 1 and days 1-14 of each subsequent cycle,', 'INTERVENTION 2: ', ' Arm 2', ' Capecitabine 1000 mg/m... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f25d63c8-9033-4db6-9c15-2151d82e2a6d | |
Comparison | Eligibility | NCT00209092 | NCT00631852 | A patient with a Histologically confirmed breast cancer would be accepted for the primary trial and the secondary trial. | Contradiction | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00209092', 'Intervention': ['INTERVENTION 1: ', ' Arm A:Sequential Therapy', ' Docetaxel will be given at 100mg/m^2 intravenously Day1 every 3 weeks for 4 cycles followed by capecitabine 1000 mg/m^2 twice a day by mouth D1-14 every 3 weeks for 4 cycles (total 8 cycles) (total 24 weeks).', 'I... | {'Clinical Trial ID': 'NCT00631852', 'Intervention': ['INTERVENTION 1: ', ' American Ginseng Root', ' four, 250mg tablets daily 5-14 days prior to surgery', ' American Ginseng root: four, 250mg tablets daily 5-14 days prior to surgery'], 'Eligibility': ['Inclusion Criteria:', ' Patients with cytologically confirmed... | 5ab5f2e8-d1cf-4789-86b4-e2f6dbf443ea |
Single | Results | NCT02308020 | There were 23 participants in cohort 1 of the primary trial with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT02308020', 'Intervention': ['INTERVENTION 1: ', ' Part A Abemaciclib: HR+, HER2+ Breast Cancer', ' Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants wit... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4fd10abc-81d1-44f4-825a-26e2eaeae979 | |
Single | Intervention | NCT00089973 | the primary trial uses a 3 week cycle for SB-715992 administration, and the study lasts for 21 cycles. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00089973', 'Intervention': ['INTERVENTION 1: ', ' SB-715992', ' The eligible participants were administered Ispinesib, intravenously as a one-hour infusion on Day 1 of every 21-day treatment cycle, at a dose of 18 mg/m^2. The dosing was repeated for up to multiple cycles, until disease progr... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a12a46de-9d3e-4c6a-becb-d43653040bf0 | |
Comparison | Intervention | NCT01017549 | NCT01390064 | the secondary trial has 5 more patients cohorts than the primary trial. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT01017549', 'Intervention': ['INTERVENTION 1: ', ' Electronic Brachytherapy', ' Radiation therapy was delivered using the 510(k) cleared Xoft Axxent System. Accelerated partial breast irradiation is the method of radiation therapy administration that has been commonly used by physicians using... | {'Clinical Trial ID': 'NCT01390064', 'Intervention': ['INTERVENTION 1: ', ' Initial Cohort', ' Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms', ' Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimoto... | 66ee10ac-1bfe-44d6-9b91-8a2bb1983606 |
Single | Adverse Events | NCT02115984 | A total of 3 patients in cohort 1 of the primary trial experience a Herpes related adverse event. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT02115984', 'Intervention': ['INTERVENTION 1: ', ' Chemotherapy & Panagen', ' Chemotherapy: Chemotherapy course includes 500 mg/m2 cyclophosphan, 50 mg/m2 doxorubicin, and 500 mg/m2 fluorouracil administered intravenously in one day.', ' Panagen 5 mg tablet by mouth every 2-3 h (six times a ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 714c540c-1fa1-47c7-ac13-1e8f056d1e31 | |
Comparison | Adverse Events | NCT00688740 | NCT00191815 | The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT00688740', 'Intervention': ['INTERVENTION 1: ', ' TAC (Docetaxel)', ' docetaxel in combination with doxorubicin and cyclophosphamide', 'INTERVENTION 2: ', ' FAC (5-fluorouracil)', ' 5-fluorouracil in combination with doxorubicin and cyclophosphamide'], 'Eligibility': ['Inclusion Criteria:'... | {'Clinical Trial ID': 'NCT00191815', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine + Cisplatin', ' Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).', ' Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).'], 'Eligibility': ... | 3948b30d-934d-485c-b324-b3571e2957a3 |
Single | Adverse Events | NCT01166763 | the primary trial recorded 4 life-threatening adverse events. | Contradiction | [
0,
1,
2,
3,
4
] | [] | {'Clinical Trial ID': 'NCT01166763', 'Intervention': ['INTERVENTION 1: ', ' High Dose Vitamin D3 (10,000 IU Weekly)', ' Group/Cohort Label vitamin D3', ' vitamin D3: oral capsules, 10,000 IU per week for 6 months'], 'Eligibility': ['Inclusion Criteria:', ' Subjects must be premenopausal women age 55 or younger, and... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 45cf29ce-25f5-4719-8468-69d94893c9e7 | |
Single | Eligibility | NCT01823991 | Patients with metallic vascular clips placed to prevent bleeding from conditions such as intracranial aneurysms, are elligible for the primary trial. | Contradiction | [
9,
19
] | [] | {'Clinical Trial ID': 'NCT01823991', 'Intervention': ['INTERVENTION 1: ', ' A - Cognutrin #1', ' Cognutrin Treatment Time 1', 'INTERVENTION 2: ', ' B - Cognutrin #2', 'Cognutrin Time 2.'], 'Eligibility': ['Inclusion Criteria:', ' Cases with Stage II-IIIA Breast Cancer that have completed adjuvant treatment with ant... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7502090d-1bcb-4be9-9358-81afb9440a17 | |
Comparison | Eligibility | NCT01840163 | NCT02005549 | the primary trial and the secondary trial do not exclude patients with concurrent systemic antitumor therapy. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT01840163', 'Intervention': ['INTERVENTION 1: ', ' CanSORT Online Tool (Intervention)', ' Comprehensive (interactive) version of decision tool', ' CanSORT Online Tool', 'INTERVENTION 2: ', ' Static Version of CanSORT Tool (Control)', ' Static version (non-interactive) version of CanSORT de... | {'Clinical Trial ID': 'NCT02005549', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab+Docetaxel+Capecitabine', ' Participants received bevacizumab, 15 mg/kg IV, followed by docetaxel 75 mg/m^2 IV on Day 1 and capecitabine 950 mg/m^2 PO BID within 30 minutes after the end of a meal, starting the evening of Day 1 and... | 89f84928-82a9-413e-ab25-400657002c55 |
Single | Adverse Events | NCT00930930 | The most frequent adverse event in cohort 1 of the primary trial was lymphopenia. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29
] | [] | {'Clinical Trial ID': 'NCT00930930', 'Intervention': ['INTERVENTION 1: ', ' Cisplatin and Paclitaxel + RAD001', ' Cisplatin 25 mg/m2 IV weekly + RAD001 5 mg PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + RAD001 5 mg PO daily for 11 weeks', ' cisplatin: Given IV', ' everolimu... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 79dbf7bf-e08d-4eae-a804-0daeb83d6f01 | |
Single | Results | NCT01381874 | The Exemestane group in the primary trial had a better median Progression-Free Survival than the Abiraterone Acetate + Prednisone group, however the patient with the maximum PFS was in the Abiraterone Acetate + Prednisone group. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01381874', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' Participants received exemestane tablet as oral dose of 25 milligram (mg) per day in 28-day treatment cycles until disease progression, unacceptable toxicity, or death (up to 3 years).', 'INTERVENTION 2: ', ' Abiraterone Aceta... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c9ff5b91-cec7-4da7-b1cd-f08f3874e8ed | |
Comparison | Adverse Events | NCT00777101 | NCT00559845 | There were no depressed patients in either the primary trial or the secondary trial, however there was one suicide attempt in cohort 2 of the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00777101', 'Intervention': ['INTERVENTION 1: ', ' Neratinib', ' Neratinib', ' Neratinib: Tablets, 240mg once per day until disease progression or unacceptable toxicity', 'INTERVENTION 2: ', ' Lapatinib+Capecitabine', ' Lapatinib plus Capecitabine', ' Lapatinib: Tablets 1250mg once per da... | {'Clinical Trial ID': 'NCT00559845', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab', ' FEC, followed by paclitaxel, given concomitantly with bevacizumab for approximately 3-12 months.', ' FEC: 5-Fluorouracil 600 mg/m^2 i.v. bolus over 15 min; epirubicin 90 mg/m^2 i.v. infusion over 1 hour; cyclophosphamide 600 ... | 23040754-d1ad-4660-aacf-3298aefa5dae |
Single | Adverse Events | NCT01033032 | The only adverse event recorded in the primary trial was one single case of pleural effusion. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT01033032', 'Intervention': ['INTERVENTION 1: ', ' Amrubicin', ' Systemic therapy with amrubicin'], 'Eligibility': ['Inclusion Criteria:', ' Females >=18 years of age.', ' Histologic diagnosis of HER2-negative breast cancer. HER-2 negativity must be confirmed by one of the following:', ' F... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e3be834c-c311-4132-8529-d354b9e620b9 | |
Single | Eligibility | NCT01326481 | Patients with Myocardial Infarction,percutaneous transluminal coronary angioplasty or Deep vein thrombosis within the last 2 - 6 months are eligible for the primary trial. | Contradiction | [
10,
18
] | [] | {'Clinical Trial ID': 'NCT01326481', 'Intervention': ['INTERVENTION 1: ', ' Carotuximab (TRC105) Plus Capecitabine', ' All patients received TRC105 + capecitabine TRC105: IV (7.5 or 10 mg/kg weekly) Capecitabine: oral (1,000 mg/m2 BID)'], 'Eligibility': ['Inclusion Criteria:', ' Histologically proven advanced solid ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8115b5e3-e178-433b-b114-09d97daaa8d7 | |
Comparison | Adverse Events | NCT00333775 | NCT00201864 | There are several cardiac adverse events recorded in the primary trial, but not a single one in the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT00333775', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel 100 mg/m^2 Plus Placebo', ' Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day ... | {'Clinical Trial ID': 'NCT00201864', 'Intervention': ['INTERVENTION 1: ', ' Exemestane and Fulvestrant', ' Combination of daily exemestane 25 mg with monthly 250 mg Fulvestrant injection', ' Exemestane: 25 mg orally per day', ' Fulvestrant: 250 mg IM starting on Day 8 and then every 28 days.'], 'Eligibility': ['Inc... | bbcfc019-2d60-413f-88f9-04cacec55e30 |
Single | Eligibility | NCT00232479 | Patients with HER2 positive breast or colon carcinoma are eligible for the primary trial. | Contradiction | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT00232479', 'Intervention': ['INTERVENTION 1: ', ' Group 1', ' patients received dose dense herceptin, carboplatin and taxotere'], 'Eligibility': ['Inclusion Criteria:', ' HER-2 overexpressing breast cancer', ' Clinical stage 2-3B', ' Normal ejection fraction', 'Exclusion Criteria:', ' Me... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e7899445-9b80-4429-b4c3-d47bd36a2347 | |
Single | Eligibility | NCT00754845 | Patients who received over 5 years of anastrozole therapy, completed 2 years prior, are eligible for the primary trial. | Entailment | [
2,
3
] | [] | {'Clinical Trial ID': 'NCT00754845', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' Patients receive oral letrozole once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.', ' letrozole: Given orally', 'INTERVENTION 2: ', ' Placebo', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2a50cc2a-281b-4bc6-9f18-6bd9686c682d | |
Single | Results | NCT01151046 | The placebo group in the primary trial had a much lower Median PFS than the MM-121 cohort. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01151046', 'Intervention': ['INTERVENTION 1: ', ' MM-121 + Exemestane', ' MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week, plus exemestane (25 mg) administered orally once per day', 'INTERVENTION 2: ', ' Placeb... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 26419cec-e256-46a7-9026-94dbe026c63d | |
Comparison | Results | NCT02336737 | NCT01432886 | the secondary trial is testing for the DLT of its interventions, whereas the primary trial is evaluating the dose limiting toxicity for SentiMag and SiennaXP. | Contradiction | [
0,
1,
2
] | [
0,
1
] | {'Clinical Trial ID': 'NCT02336737', 'Intervention': ['INTERVENTION 1: ', ' SiennaXP Injection', ' Single injection of SiennaXP in addition to comparator single dose of radioisotope (Technetium Tc99m Sulfur Colloid) and single dose of isosulfan blue dye.', ' Lymph node localization using the SentiMag handheld intrao... | {'Clinical Trial ID': 'NCT01432886', 'Intervention': ['INTERVENTION 1: ', ' E7389 With Weekly Trastuzumab', ' Eribulin mesylate (E7389) was administered intravenously on Day 1 and Day 8 of each 3 week cycle. Trastuzumab was administered intravenously weekly, with an initial dose of 4 mg/kg followed by 2 mg/kg for the... | 8ef93fe0-0a12-4a7e-93aa-c40af7154a57 |
Single | Results | NCT00171340 | the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density, whereas Zoledronic Acid 4 mg Delayed causes a smaller, but still positive change in Bone Mineral Density (within a certain patient demographic). | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00171340', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid 4 mg Upfront', ' Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.', 'INTERVENTION 2: ',... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f5d50d87-b419-4537-87ec-7c9d23b765db | |
Single | Intervention | NCT01797120 | Cohort 2 of the primary trial is only receiving placebo tablets, and no other medications. | Entailment | [
7,
8,
9,
3,
4,
12
] | [] | {'Clinical Trial ID': 'NCT01797120', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant & Everolimus', ' Fulvestrant Day 1 & 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus everolimus daily x 12 cycles.', ' Fulvestrant: Fulvestrant 500 mg Day 1 & 15 of Cycle 1, then 500 mg Day 1... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f52ab54b-7a78-4449-9dfe-5fc67323e5c2 | |
Single | Adverse Events | NCT00426556 | There were more than 3 cases of Febrile neutropenia, Leukopenia and Neutropenia across all cohorts in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
14,
15,
16,
17,
18
] | [] | {'Clinical Trial ID': 'NCT00426556', 'Intervention': ['INTERVENTION 1: ', ' Phase I - RAD001 5mg + PT, Daily', ' Daily dosing schedule of Everolimus 5mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab', 'INTERVENTION 2: ', ' Phase I - RAD001 10mg + PT, Daily', ' Daily dosing schedule of Everolimus 1... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c0277198-6eef-4cf3-9527-dea5d01a4000 | |
Single | Eligibility | NCT01582971 | In order to participate in the primary trial, participants must have 20/20 vision and a hiistologically confirmed, measurable, invasive breast carcinoma. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [] | {'Clinical Trial ID': 'NCT01582971', 'Intervention': ['INTERVENTION 1: ', ' Week 5 Intervention Group', ' Reflexology: 4 weekly foot reflexology sessions delivered by friend/family member.', ' Friend/family member was trained in foot reflexology protocol by certified reflexologist.', ' Friend/family member provides... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | fea87f74-c8ef-4efd-944a-053f5e5a752f | |
Single | Adverse Events | NCT00394251 | There were more cases of Cardiac failure than Pericardial effusion recorded in cohort 1. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00394251', 'Intervention': ['INTERVENTION 1: ', ' ABI-007 Subset', ' 260 mg/m2 ABI-007 (Abraxane) plus Bevacizumab for 4 cycles (weeks 9-16); Bevacizumab (weeks 17-46). Weeks 1-8 are excluded from this subset.', 'INTERVENTION 2: ', ' AC --> ABI-007', ' Adriamycin and Cytoxan plus Bevacizum... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 43560d8e-0767-40ce-b2fb-1b8dda231bdf | |
Single | Adverse Events | NCT01998906 | The same number of cases of Neutropenia, Febrile neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial. | Contradiction | [
0,
2,
3,
4
] | [] | {'Clinical Trial ID': 'NCT01998906', 'Intervention': ['INTERVENTION 1: ', ' HER2+ TC', ' Participants with HER2+ breast cancer received treatment as follows:', ' Cycles 1-3 (3-week cycles): trastuzumab 8 mg/kg, IV on Day 1 (Cycle 1 only; 6 mg/kg in Cycles 2 and 3), doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2417fea2-7c8e-4f03-a918-c3cfcbe97425 | |
Comparison | Eligibility | NCT01904903 | NCT01663727 | Patients must have LVEF < 50% to be eligible for the primary trial. | Entailment | [
3
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18
] | {'Clinical Trial ID': 'NCT01904903', 'Intervention': ['INTERVENTION 1: ', ' HER2 Therapies, Cardiac Medications', ' Cardiac intervention - beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses', ' Oncology intervention - patients will receive one of the three following HER2 targeted therapies at t... | {'Clinical Trial ID': 'NCT01663727', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel+Placebo', ' Participants received paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.', 'INT... | 55391bc6-41a8-4686-82d6-6814166d32b8 |
Single | Results | NCT00091832 | cohort 1 of the primary trial had a negative (median) Percent Change From Baseline of urea-adjusted Urinary N-telopeptide (uNTx/Ur). | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00091832', 'Intervention': ['INTERVENTION 1: ', ' Bisphosphonate IV Q4W', ' Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion', 'INTERVENTION 2: ', ' Denosumab 30 mg Q4W', ' Denosumab 30 mg by subcutaneous injection every 4 weeks (Q4W)'], 'Eligibility': ['Inclusion Crit... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 06d25b0a-ef0d-4b6e-a8ed-c91689bfa82b | |
Comparison | Intervention | NCT02122796 | NCT01575522 | The intervention section for the primary trial does not detail the type, dosage or duration of the intervention, unlike the secondary trial. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3,
4
] | {'Clinical Trial ID': 'NCT02122796', 'Intervention': ['INTERVENTION 1: ', ' Patients Undergoing Mastectomy Surgery', ' Number of individuals having mastectomy surgery who were approached for participation in the trial'], 'Eligibility': ['Inclusion Criteria:', ' Women', ' 18 years or older', ' Undergoing mastectomy... | {'Clinical Trial ID': 'NCT01575522', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Tivantinib)', ' Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection at baseline and periodically dur... | 15553950-e26b-4fbb-a576-8455e6bb7b23 |
Comparison | Intervention | NCT02606708 | NCT02504424 | Only patients in the primary trial receive 40.5 Gy of Accelerated Intensity Modulated Radiation Therapy, patients in the secondary trial receive no radiotherapy whatsoever. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02606708', 'Intervention': ['INTERVENTION 1: ', ' Accelerated Intensity Modulated Radiation Therapy (AIMRT)', ' All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IM... | {'Clinical Trial ID': 'NCT02504424', 'Intervention': ['INTERVENTION 1: ', ' AeroForm Tissue Expander', ' AeroForm Tissue Expansion inflation with carbon dioxide by remote control', ' AeroForm Tissue Expander: The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by rem... | 58838d25-bf87-44e7-a604-23468d67a1e3 |
Single | Results | NCT01959490 | In total only 20% of participants in the primary trial did not achieve Pathological Complete Response. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01959490', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1P (HER2 Positive)', ' Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 02426c34-ebf9-4bd4-9d55-86fad89baf20 | |
Comparison | Adverse Events | NCT00618826 | NCT02040857 | the primary trial and the secondary trial only record 4 of the same adverse events. | Entailment | [
0,
3,
8,
10,
5
] | [
0,
9,
3,
6,
11
] | {'Clinical Trial ID': 'NCT00618826', 'Intervention': ['INTERVENTION 1: ', ' Treatment', ' Paclitaxel / Gemcitabine'], 'Eligibility': ['Inclusion Criteria:', ' Patient must be 18 years of age or older with histologically confirmed breast cancer and clinical evidence of metastatic disease.', ' Patients must have meas... | {'Clinical Trial ID': 'NCT02040857', 'Intervention': ['INTERVENTION 1: ', ' Palbociclib With Adjuvant Endocrine Therapy', ' Palbociclib 125 mg PO qd 21 days on, 7 days off', ' Endocrine Therapy: Tamoxifen 20mg, Letrozole 2.5mg, Anastrozole 1mg, or Exemestane 25mg PO qd'], 'Eligibility': ['Inclusion Criteria:', ' Pa... | 9e28c807-8d88-4eea-87ee-48a42bd002ab |
Single | Eligibility | NCT02600923 | Patients with Leukemia, Hepatitis or Polycystic Kidney Disease cannot be included in the primary trial. | Entailment | [
0,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT02600923', 'Intervention': ['INTERVENTION 1: ', ' Palbociclib+Letrozole', ' Participants received palbociclib orally once daily at 125 mg for 21 days followed by 7 days off treatment for each 28-day cycle, and letrozole orally at 2.5 mg QD as a continuous daily dosing schedule. Participants ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 80ac126e-c756-4031-9541-e50d51c18b38 | |
Single | Intervention | NCT02953860 | Patients in the primary trial receive less mg of Enzalutamide than Fulvestrant on a weekly basis. | Contradiction | [
3
] | [] | {'Clinical Trial ID': 'NCT02953860', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant With Enzalutamide', ' 500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given, in conjunction with Fulvestrant, PO daily.', ' Fulvestrant w... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1a1d7d1d-ec49-46db-b6bc-dfd94575e46c | |
Single | Eligibility | NCT00717886 | Prior axillary surgery, axillary radiation, breast cancer and breast radiation are not permitted for entry to the primary trial. | Entailment | [
3,
4,
5,
6,
7
] | [] | {'Clinical Trial ID': 'NCT00717886', 'Intervention': ['INTERVENTION 1: ', ' Upper Extremity Lymphatic Mapping for Breast Cancer Patients', ' Patients with documented axillary metastases (Stage II breast cancer) will undergo subdermal injection of technetium sulfur colloid (TSC) into the ipsilateral upper extremity ap... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 68a9f2f0-cf11-4cd4-847c-53b8befd6002 | |
Single | Eligibility | NCT00756717 | Patients with cytologically confirmed, non metastatic, early stage invasive breast cancer with an Allred score of 1 are excluded from the primary trial. | Entailment | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT00756717', 'Intervention': ['INTERVENTION 1: ', ' MK-0752', ' Oral gamma-secretase inhibitor drug MK-0752, 350 mg for three days, four days off, then three days on, over a period of 10 days', ' MK-0752: Women who are post menopausal will receive letrozole 2.5 mg by mouth one time per day fo... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9bcd40cf-8221-4383-8891-76a4bcc5c766 | |
Single | Results | NCT00291577 | It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 6, 24 or 12 hours. | Contradiction | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT00291577', 'Intervention': ['INTERVENTION 1: ', ' Sunitinib in Combination With Docetaxel', ' Sunitinib (SU011248) orally (PO) for 2 weeks every 3 weeks (2 weeks on, then 1 week off = Schedule 2/1) starting on Day 2 (Cycle 2, Day 3 only for those subjects included in the Pharmacokinetic [PK]... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 341156fc-9cbd-492f-8e9e-8fbf98191625 | |
Single | Adverse Events | NCT00201851 | There were no cases of Oesophageal spasming observed in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00201851', 'Intervention': ['INTERVENTION 1: ', ' A - Scheduled Surgery', ' Patient scheduled for mid-luteal phase surgical oophorectomy/mastectomy plus Tamoxifen', ' Tamoxifen: 20 mg po daily x 5 years', ' Surgery: Oophorectomy: Group A-Surgical oophorectomy and mastectomy in estimated 5 ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 44ae021e-241b-4dbf-b88f-0b9d41eab555 | |
Single | Adverse Events | NCT00080301 | There were 5 more cases of THROMBOCYTOPENIA in cohort 2 of the primary trial, than in cohort 1. | Entailment | [
0,
7,
13,
20
] | [] | {'Clinical Trial ID': 'NCT00080301', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone + Capecitabine', ' Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each 21-day cycle, plus oral capecitabine 1000 mg/m2 twice a day (BID) x 14 days', 'INTERVENTION 2: ', ' Capecitabine', ' Cap... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 523a44a3-6b90-4be7-ab46-6b6addd7b5b9 | |
Comparison | Intervention | NCT03475992 | NCT03106077 | Participants in the primary trial receive different interventions depending on their cancer hormone status, so Triple-Negative patients are seperated from HER2+ patients for example, whereas all patients in the secondary trial took the same intervention. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT03475992', 'Intervention': ['INTERVENTION 1: ', ' Pre-diagnosed Breast Cancer - Biopsy Confirmed', ' Low-power microwave breast imaging system.', ' Core needle biopsy performed 14 days before the microwave breast investigation', ' Low-power microwave breast imaging system: Investigate the ... | {'Clinical Trial ID': 'NCT03106077', 'Intervention': ['INTERVENTION 1: ', ' Cohort A: Advanced Triple-Negative Breast Cancer (TNBC)', ' 6 mg/kg IMGN853 IV Q3W'], 'Eligibility': ['Inclusion Criteria:', ' Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1', ' Confirmed invasive triple-negative bre... | 258a51ca-e1f0-4d9a-88a6-8749f4822034 |
Comparison | Results | NCT00057941 | NCT01806259 | Recurrence-free Survival, used as the outcome measurement in the secondary trial and Clinical Benefit Rate, used in the primary trial are not synonymous, and represent entirely different patient characteristics. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT00057941', 'Intervention': ['INTERVENTION 1: ', ' Anastrozole and ZD1839', '[Not Specified]', 'INTERVENTION 2: ', ' Fulvestrant and ZD1839', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have estrogen and/or progesterone receptor positive histologically confirme... | {'Clinical Trial ID': 'NCT01806259', 'Intervention': ['INTERVENTION 1: ', ' Ketorolac 30 mg', ' Active drug to be compared with placebo', 'Ketorolac 30 mg IV', 'INTERVENTION 2: ', ' NaCl 0.9% 3mL', 'Ketorolac 30 mg IV'], 'Eligibility': ['Inclusion Criteria:', ' Written informed Consent age : 18-85 years weight: 50-... | 83bacd68-871a-4777-ba23-1f9a3df9227d |
Comparison | Results | NCT00369655 | NCT00091832 | One patient in the primary trial had a Confirmed tumor partial response, in contrast thirty patients in the secondary trial had partial tumor response. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT00369655', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Ziv-afibercept)', ' Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically or cyt... | {'Clinical Trial ID': 'NCT00091832', 'Intervention': ['INTERVENTION 1: ', ' Bisphosphonate IV Q4W', ' Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion', 'INTERVENTION 2: ', ' Denosumab 30 mg Q4W', ' Denosumab 30 mg by subcutaneous injection every 4 weeks (Q4W)'], 'Eligibility': ['Inclusion Crit... | fedc0601-fd6b-4f9b-9ce7-6d9ee2e591e9 |
Single | Adverse Events | NCT00391092 | In total there were 32 cases of Febrile neutropenia in the primary trial, and only one case of anemia. | Contradiction | [
0,
2,
4,
12,
14,
16
] | [] | {'Clinical Trial ID': 'NCT00391092', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + Docetaxel', " Trastuzumab 8 mg/kg loading dose administered intravenously on Day 1 of Cycle 1, followed by docetaxel 100 mg/m^2 on Day 2 of Cycle 1. Then a maintenance dose of trastuzumab at 6 mg/kg and docetaxel at 100 mg/m^2 w... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1a451f2e-0818-4a86-8808-0e4cce700aef | |
Comparison | Adverse Events | NCT01325207 | NCT02429427 | Patients participating in the primary trial and the secondary trial experienced a variety of cardiac problems. | Entailment | [
2
] | [
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT01325207', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1 - Trastuzumab 10mg IT 2/Week', ' Intrathecal Trastuzumab 10 mg IT will be administered in Cohort 1 of dose escalation.', ' Trastuzumab: Trastuzumab will be administered twice per week for 4 weeks, then once per week for 4 weeks, and... | {'Clinical Trial ID': 'NCT02429427', 'Intervention': ['INTERVENTION 1: ', ' Celecoxib', ' Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.', ' Celecoxib: Patients will receive 400mg of Celecoxib o... | 52333afb-0e7a-4823-ae9b-746e0ce57c8c |
Single | Adverse Events | NCT00005908 | There was only one patient cohort in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00005908', 'Intervention': ['INTERVENTION 1: ', ' Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine', ' Docetaxel 75 mg/m^2 intravenous day 1, capecitabine 1000 mg/m^2 orally twice daily day 2-15 for 4 cycles Once the dose was deemed to be too toxic, subsequent patients were enrolled on dose B.... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4216b27f-4d3e-4029-9637-2e6dade15b73 | |
Comparison | Adverse Events | NCT00246090 | NCT00266799 | Cohort 1 of the primary trial 0.0015% less total adverse events than cohort 2 of the secondary trial. | Contradiction | [
0,
1
] | [
15,
16
] | {'Clinical Trial ID': 'NCT00246090', 'Intervention': ['INTERVENTION 1: ', ' E7389 1.4 mg/m^2', ' E7389 1.4 mg/m^2 intravenous bolus given over 2-5 minutes on Days 1 and 8 every 21 days.'], 'Eligibility': ['Inclusion Criteria:', ' Female patients with histologically or cytologically confirmed carcinoma of the breast.... | {'Clinical Trial ID': 'NCT00266799', 'Intervention': ['INTERVENTION 1: ', ' Pegylated Liposomal Doxorubicin (PLD)', ' PLD 50 mg/m^2 was administered intravenously once every 28 days. Each cycle was repeated until progress or unacceptable toxicity.', 'INTERVENTION 2: ', ' Capecitabine', ' Capecitabine 1250 mg/m^2, i... | 14a32a42-424b-4b97-bae9-05f4bb2b415b |
Single | Eligibility | NCT00030823 | Patients with stage I, II, III or IV breast cancer may be eliglbe for the primary trial. | Entailment | [
4,
2,
11
] | [] | {'Clinical Trial ID': 'NCT00030823', 'Intervention': ['INTERVENTION 1: ', ' Vaccine', ' Patients receive Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine with QS21 adjuvant subcutaneously weekly on weeks 1, 2, 3, 7, and 19.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Diagnosis of breast ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4d83c630-d767-40cf-9aec-c871c6fc7f38 | |
Single | Eligibility | NCT03371732 | Any patients with Karnofsky Index < 80 are eligible for the primary trial. | Contradiction | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT03371732', 'Intervention': ['INTERVENTION 1: ', ' Arm 1', ' Arm 1: Motivational Intervention group', ' Motivational Intervention group: Participants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4fd230f2-caf1-44d6-81f2-4f51dda6da3a | |
Single | Results | NCT00764322 | The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 ng/mL over 4 months. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00764322', 'Intervention': ['INTERVENTION 1: ', ' Ultra-rapid Metabolizers', ' Those with the highest transformation of the CYP2D6 genotype to allelic activity', 'INTERVENTION 2: ', ' Extensive Metabolizers', ' Those with the most normal transformation of the CYP2D6 genotype to allelic act... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7a3d1ca7-8776-4ace-bbc0-107635b93583 | |
Single | Eligibility | NCT02040857 | Only men and postmenopausal women are eligible for the primary trial. | Contradiction | [
2
] | [] | {'Clinical Trial ID': 'NCT02040857', 'Intervention': ['INTERVENTION 1: ', ' Palbociclib With Adjuvant Endocrine Therapy', ' Palbociclib 125 mg PO qd 21 days on, 7 days off', ' Endocrine Therapy: Tamoxifen 20mg, Letrozole 2.5mg, Anastrozole 1mg, or Exemestane 25mg PO qd'], 'Eligibility': ['Inclusion Criteria:', ' Pa... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e95902f1-bf4f-4bb5-8f48-4fa5ba6425d0 | |
Comparison | Eligibility | NCT01966471 | NCT00981812 | A patient who had a breast-conserving surgery in the year prior to study entry would be excluded from both the primary trial and the secondary trial. | Contradiction | [
0,
4,
5
] | [
5,
12
] | {'Clinical Trial ID': 'NCT01966471', 'Intervention': ['INTERVENTION 1: ', ' Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane', ' Trastuzumab and pertuzumab were administered concurrently for up to a total duration of 1 year (up to 18 cycles [1 Cycle = 21 days]) with the taxane (docetaxel or paclitaxel) c... | {'Clinical Trial ID': 'NCT00981812', 'Intervention': ['INTERVENTION 1: ', ' Lesions Visualized Using Positron Emission Mammography (PEM)', ' Total lesions visualized using positron emission mammography.'], 'Eligibility': ['Inclusion Criteria:', ' female', ' subject is 25-100 years of age', ' subjects has at least ... | 1196db61-0846-4185-afc9-dc4b2fccd059 |
Comparison | Intervention | NCT02005887 | NCT00050011 | All Participants in the primary trial and the secondary trial are receiving the same daily dose of oral Letrozole for the same duration of time. | Entailment | [
0,
1,
2,
3,
4
] | [
0,
1,
2,
3,
4
] | {'Clinical Trial ID': 'NCT02005887', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Triptorelin + Letrozol', ' Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles', ' Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycle... | {'Clinical Trial ID': 'NCT00050011', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid Upfront', ' Participants in the upfront arm received Zoledronic Acid 4 mg i.v. on Day 1 and every 6 months until disease progression (recurrence)or the end of study. Participants also received Letrozole 2.5 daily plus calcium ... | 567ec6e3-87aa-4a4a-94b8-ebdf2e0cbf64 |
Single | Adverse Events | NCT00490646 | Cohort 1 of the primary trial had 25% more patients experiencing Cholecystitis than cohort 2. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [] | {'Clinical Trial ID': 'NCT00490646', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab 2 mg/kg + Ixabepilone 40 mg/m^2 IV', ' trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + ixabepilone 40 mg/m^2 intravenous (IV) over 3 hours once every 21 days (using a 21-day cycle); until disease progression or unacceptabl... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7e629f62-2981-4462-a4c1-f0cc9c24777a | |
Single | Intervention | NCT00600340 | Cohorts 1 of the primary trial recieves Bevacizumab at a higher frequency than cohort 2. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00600340', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab Plus Paclitaxel', ' Bevacizumab 10 mg/kg intravenous (i.v.), days 1 and 15, every 4 weeks, Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks', 'INTERVENTION 2: ', ' Bevacizumab Plus Capecitabine', ' Bevacizumab 15 mg/kg i.v.,... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c660faec-58d8-4ba9-8e18-1775b1135819 | |
Single | Adverse Events | NCT03078751 | Cohort 2 of the primary trial reported one case of AML. | Contradiction | [
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT03078751', 'Intervention': ['INTERVENTION 1: ', ' Ribociclib + Adjuvant Endocrine Therapy (ET)', ' Patients in this arm took Ribociclib in combination with standard adjuvant endocrine therapy. ET was one of these 4: Letrozole, Anastrozole, Exemestane, Tamoxifen (Tamoxifen no longer permitted... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a6fcfea0-eacd-4a04-92a8-55a0c3c8bfb2 | |
Comparison | Intervention | NCT01830933 | NCT01224678 | Patients in the primary trial do not receive any extra medication for the study, whereas in the secondary trial they are given an oral medication. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
5
] | {'Clinical Trial ID': 'NCT01830933', 'Intervention': ['INTERVENTION 1: ', ' Usual Care', ' Usual Care is the comparison Clinic Patients, where there is no change in their standard or usual care.', 'INTERVENTION 2: ', ' BreastCARE Intervention', ' Intervention Clinic Patients: The participants will answer questions ... | {'Clinical Trial ID': 'NCT01224678', 'Intervention': ['INTERVENTION 1: ', ' Placebo', ' Patients receive oral placebo once daily for 12 months.', 'INTERVENTION 2: ', ' Vitamin D', ' Patients receive oral vitamin D (2000 IU) once daily for 12 months.'], 'Eligibility': ['Premenopausal women 55 years of age or younger... | 3ee5742b-6bc3-400f-92eb-641384a75201 |
Single | Eligibility | NCT01823991 | Patients with irrational fear of confined spaces are not elligible for the primary trial. | Entailment | [
9,
19
] | [] | {'Clinical Trial ID': 'NCT01823991', 'Intervention': ['INTERVENTION 1: ', ' A - Cognutrin #1', ' Cognutrin Treatment Time 1', 'INTERVENTION 2: ', ' B - Cognutrin #2', 'Cognutrin Time 2.'], 'Eligibility': ['Inclusion Criteria:', ' Cases with Stage II-IIIA Breast Cancer that have completed adjuvant treatment with ant... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f6af788f-ee96-4308-8dec-12d0c46e957a | |
Comparison | Results | NCT00118157 | NCT01401959 | Participants in the primary trial had a higher likelihood of achieving 2 Year Disease-Free Survival than those in either cohort of the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT00118157', 'Intervention': ['INTERVENTION 1: ', ' Arm 1', ' Patients receive oral lapatinib and oral tamoxifen once daily on days 1-28.', ' lapatinib ditosylate: Given orally', ' tamoxifen citrate: Given orally'], 'Eligibility': ['Inclusion Criteria:', ' Primary adenocarcinoma of the brea... | {'Clinical Trial ID': 'NCT01401959', 'Intervention': ['INTERVENTION 1: ', ' Cohort A: Triple-negative Breast Cancer Patients', ' Patients with triple-negative breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every... | 2e09a2ec-149e-46b4-b60a-ed421fdbc9b3 |
Single | Results | NCT01231659 | Less than 20 the primary trial participants achieved partial response (PR). | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01231659', 'Intervention': ['INTERVENTION 1: ', ' Everolimus + Letrozole', ' All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol.'], 'Eligibility': ['Inclusion Criteria:'... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e0b7a120-8735-413d-9a47-8508b2feffb3 | |
Single | Eligibility | NCT00981812 | Women who have undergone a breast enlargement procedure, and have since had the implants removed, are excluded from the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00981812', 'Intervention': ['INTERVENTION 1: ', ' Lesions Visualized Using Positron Emission Mammography (PEM)', ' Total lesions visualized using positron emission mammography.'], 'Eligibility': ['Inclusion Criteria:', ' female', ' subject is 25-100 years of age', ' subjects has at least ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1393c5d9-d2be-433b-9abf-9449b46588c4 | |
Comparison | Intervention | NCT00195013 | NCT00620373 | Cohort 2 of the primary trial is a placebo group, the secondary trial does not have a placebo group. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00195013', 'Intervention': ['INTERVENTION 1: ', ' Glutamine', ' 10 grams three times a day (orally) for four days and then stop', ' glutamine: 10 grams three times a day (orally) for four days and then stop', 'INTERVENTION 2: ', ' Placebo', ' 10 grams three times a day (orally) for four d... | {'Clinical Trial ID': 'NCT00620373', 'Intervention': ['INTERVENTION 1: ', ' Mammography Only', ' For this reporting arm, the interpretation and analysis was done with mammography only.', 'INTERVENTION 2: ', ' Gamma Imaging', ' For this reporting arm, the interpretation and analysis was done with gamma imaging only.... | abfa5699-2863-4319-9386-4b359f2062f2 |
Single | Eligibility | NCT01196052 | Participants in the primary trial must be willing to undergo anthracycline-based chemotherapy, or have previously received either cyclophosphamide or epirubicin. | Entailment | [
0,
4
] | [] | {'Clinical Trial ID': 'NCT01196052', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine', ' Trastuzumab emtansine 3.6 mg/kg was administered intravenously on Day 1 of each 3-week treatment cycle up to a maximum of 17 cycles.'], 'Eligibility': ['Inclusion Criteria:', ' Adult patients 18 years of age.', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4038f7c3-87e2-47d6-811b-fd2b21679577 | |
Single | Eligibility | NCT01031446 | Sarah has been experiencing epileptic seizures from a brain tumor. This excludes her from participating in the primary trial. | Entailment | [
5
] | [] | {'Clinical Trial ID': 'NCT01031446', 'Intervention': ['INTERVENTION 1: ', ' RAD001 and Cisplatin and Paclitazel', ' Cisplatin intravenously (IV) weekly for 3 weeks, then 1 week of rest; paclitaxel IV weekly for 3 weeks, then 1 week of rest. Everolimus (RAD001) po daily. One cycle = 4 weeks'], 'Eligibility': ['DISEASE... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5097f4cd-9118-473d-a2a0-72f0cd12c7a5 | |
Single | Intervention | NCT00956813 | All the primary trial subjects are required to take the intervention PO daily. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00956813', 'Intervention': ['INTERVENTION 1: ', ' Flaxseed', ' Patients receive 1 Nutrigrad™ flaxseed bar containing 7.5 grams flaxseed, 410 mg lignans,once daily.', 'INTERVENTION 2: ', ' Placebo', ' Patients Identical looking bar with same calorie and total fat content but without flaxsee... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 68e6a088-ab80-4a89-90d4-39308bccb1c2 | |
Comparison | Intervention | NCT00446030 | NCT00975676 | the primary trial and the secondary trial have no overlap in the drugs they use for their interventions, however they both have placebo groups. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00446030', 'Intervention': ['INTERVENTION 1: ', ' Stratum 1: TAC + Bevacizumab', ' HER2 negative participants were administered chemotherapy with docetaxel, doxorubicin and cyclosphosphamide (TAC) + bevacizumab every 3 weeks for 6 cycles, and maintenance therapy with bevacizumab every 3 week... | {'Clinical Trial ID': 'NCT00975676', 'Intervention': ['INTERVENTION 1: ', ' Triptorelin Plus Tamoxifen', ' Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years.', 'INTERVENTION 2: ', ' Triptorelin Plus Exemestane', ' Determination of estrogen leve... | a4c49b44-91b3-4a3c-bfbf-b3758cc398f1 |
Comparison | Eligibility | NCT00971737 | NCT00392392 | Patients with a positive FISH result are eligible for the secondary trial, but not for the primary trial. | Entailment | [
0,
1,
2,
3
] | [
0,
3
] | {'Clinical Trial ID': 'NCT00971737', 'Intervention': ['INTERVENTION 1: ', ' Cyclophosphamide and Vaccine Only', ' Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of ... | {'Clinical Trial ID': 'NCT00392392', 'Intervention': ['INTERVENTION 1: ', ' Nab-Paclitaxel/Bevacizumab/Trastuzumab', ' Patients received treatment with nab-paclitaxel (100 mg/m2 IV days 1, 8, 15) and carboplatin (AUC 6 IV day 1) every 28 days for 6 cycles. Trastuzumab (4 mg/kg loading dose, followed by 2 mg/kg) and b... | 08917306-11b0-44ad-8f45-9a67d7f6073e |
Comparison | Intervention | NCT00073073 | NCT00054028 | There are no placebo or control groups in the primary trial or the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00073073', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' exemestane 25 mg by mouth (PO) every day for two years taken with calcium carbonate 1200 mg PO every day and vitamin D 400 IU PO every day Initially patients were initially planned to receive Celecoxib but the study was amended... | {'Clinical Trial ID': 'NCT00054028', 'Intervention': ['INTERVENTION 1: ', ' Suramin and Paclitaxel', ' Suramin will be infused weekly over 30 minutes. Four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin.'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have h... | 9702cb6a-bdb1-415f-bb99-3b740728a4ea |
Comparison | Results | NCT00706030 | NCT00171704 | participants from both cohorts of the primary trial had a drastically lower CNS Objective Response Rate than those in the secondary trial. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT00706030', 'Intervention': ['INTERVENTION 1: ', ' Neratinb 240 mg + Vinorelbine 25 mg/m² - No Prior Lapatinib', ' Neratinib 240 mg qd + Vinorelbine 25 mg/m² IV on days 1 and 8 every 3 weeks, with no prior lapatinib exposure', 'INTERVENTION 2: ', ' Neratinib 240 mg + Vinorelbine 25 mg/m² - P... | {'Clinical Trial ID': 'NCT00171704', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' 2.5 mg once daily (q.d.)orally for 5 years', 'INTERVENTION 2: ', ' Tam-Let', ' 20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years.'], 'Eligibility': ['Inclusion Criteria',... | 7afa2d1f-7922-4b09-b52a-43bd9a4788a9 |
Single | Eligibility | NCT01299038 | Joe has had an alcohol addiction for 15 years, resulting in Cirrhosis therefore he is likely to be excluded from the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT01299038', 'Intervention': ['INTERVENTION 1: ', ' Rosuvastatin 20mg', ' Rosuvastatin 20mg taken orally once a day for 4 weeks', ' rosuvastatin: Taken orally once a day for 4 weeks', 'INTERVENTION 2: ', ' Rosuvastatin 40mg', ' Rosuvastatin 40mg taken orally once a day for 4 weeks', ' rosu... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | dfd5acc2-6824-4b63-93ad-34e6a0a4c621 | |
Comparison | Eligibility | NCT03273426 | NCT01091168 | Patients with Concurrent serious uncontrolled medical disorder may be eligible for the primary trial, but are always excluded from the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
4
] | {'Clinical Trial ID': 'NCT03273426', 'Intervention': ['INTERVENTION 1: ', ' Core Needle Biopsy', ' Ultrasound-guided core needle biopsy (14G, 5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.', 'INTERVENTION 2: ', ' Vacuum-assisted Biopsy', ' Vacuum-assisted biopsy (10G, 5 core... | {'Clinical Trial ID': 'NCT01091168', 'Intervention': ['INTERVENTION 1: ', ' Vinflunine', ' Patients randomised in the test arm (arm A) received VFL at the dose of 280 mg/m² on day 1 of each cycle every 3 weeks, over a 20-minute intravenous (IV) infusion. Cycles were repeated every 3 weeks.', ' vinflunine: 280 mg/m2 ... | 97e9967e-6525-4082-bd11-8c30e14d23fd |
Single | Results | NCT00082433 | the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine, may increase OS, compared to Capecitabine alone. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00082433', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone + Capecitabine', ' Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only, plus oral capecitabine 1000 mg/m2 twice a da... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d11dd4ae-28be-4ad2-a452-4374c48f08d1 | |
Single | Adverse Events | NCT02273973 | Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than diarrhoea. | Contradiction | [
0,
3,
11
] | [] | {'Clinical Trial ID': 'NCT02273973', 'Intervention': ['INTERVENTION 1: ', ' Experimental: Taselisib + Letrozole', ' Participants received 2.5 milligrams (mg) letrozole tablets orally once daily (QD) along with taselisib tablets at 4 mg (two 2 mg tablets) orally on a 5 days-on/2 days-off schedule for a total of 16 wee... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3b6229a9-00a1-4d26-9285-6d9f6a25fd77 | |
Comparison | Eligibility | NCT00322348 | NCT00429572 | the primary trial and the secondary trial use different metrics to evaluate potential candidates' performance status. | Entailment | [
2
] | [
2
] | {'Clinical Trial ID': 'NCT00322348', 'Intervention': ['INTERVENTION 1: ', ' ZOLADEX 10.8 mg', ' ZOLADEX (goserelin acetate) 10.8 mg intramuscular depot for injection every 12 weeks', 'INTERVENTION 2: ', ' ZOLADEX 3.6 mg', ' ZOLADEX (goserelin acetate) 3.6 mg intramuscular depot for injection every 4 weeks'], 'Eligi... | {'Clinical Trial ID': 'NCT00429572', 'Intervention': ['INTERVENTION 1: ', ' Allogeneic Transplantation', ' Intravenous Fludarabine 30 mg/m^2 daily on days 1-5, and Melphalan 70 mg/m^2 on days 4 and 5 followed by blood stem cell transplant on day 7.'], 'Eligibility': ['Inclusion Criteria:', ' Recurrent or residual me... | 9eab20ad-ffc6-473f-8087-c6c3f06f356f |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.